Clinical Trials
30 trialsTesting Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
CLEAR
National Cancer Institute (NCI)
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
LATIFY
AstraZeneca
CAPRI
University of Pennsylvania
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
LOTOS
AstraZeneca
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
ATARI
Institute of Cancer Research, United Kingdom
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
AstraZeneca
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
CONCORDE
University of Leeds
AUSTRAL
Mario Negri Institute for Pharmacological Research
HUDSON
AstraZeneca
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
ATRiBRAVE
IFOM ETS - The AIRC Institute of Molecular Oncology
PHOENIX
Institute of Cancer Research, United Kingdom
Patriot
Royal Marsden NHS Foundation Trust
MONETTE
AstraZeneca